J Cancer 2021; 12(15):4710-4721. doi:10.7150/jca.58873
MicroRNA-455-5p Contributes to Cholangiocarcinoma Growth and Mediates Galangin's Anti-Tumor Effects
1. Department of Cardiology, The Third Xiangya Hospital, Central South University, Changsha, Hunan, China.
2. Department of Pharmacy, The Affiliated Changsha Hospital of Hunan Normal University, Changsha, Hunan, China.
3. Department of Cardiology, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Deng X, Zuo M, Pei Z, Xie Y, Yang Z, Zhang Z, Jiang M, Kuang D. MicroRNA-455-5p Contributes to Cholangiocarcinoma Growth and Mediates Galangin's Anti-Tumor Effects. J Cancer 2021; 12(15):4710-4721. doi:10.7150/jca.58873. Available from https://www.jcancer.org/v12p4710.htm
Fully understanding the mechanism of how Cholangiocarcinoma (CCA) development and discovering promising therapeutic drugs are important to improve patients' survival time. This study identifies that microRNA-455-5p (miR-455-5p) targets protein phosphatase 1 regulatory subunit 12A (PPP1R12A), an effect that represses mitogen-activated protein kinase (MAPK) and PI3K/AKT pathway activation, thereby controlling CCA cells survival and metastasis. Moreover, miR-455-5p expression is reduced in CCA tissues and negative correlation with PPP1R12A and PPP1R12A knockdown phenotypic mimics miR-455-5p' effects on CCA cells. Furthermore, we demonstrate that galangin inhibits CCA growth both in vitro and in vivo, which is associated with increased miR-455-5p and repressed PPP1R12A expression. In support, overexpression of miR-455-5p abrogates those galangin-mediated anti-CCA effects. These findings establish an essential role of miR-455-5p in CCA development and galangin may provide a potential therapeutic adjuvant agent for anti-CCA treatment.
Keywords: cholangiocarcinoma, microRNA, galangin, survival, metastasis